Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II irinotecan liposome + 5-FU/leucovorin + bevacizumab in first-line metastatic colorectal cancer
ChiCTR2500104331Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in metastatic colon cancer (mCRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Jun 2025; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2500104331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104331.